What Avalo Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 9 | 43 |
| Total trades | 17 | 92 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 96,789 | 741,812 |
| Disposed | 100,317 | 473,397 |
| Net activity | −3,528 | +268,415 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 16 | Open-market sale · S | −12,394 | $16.33 | −$202K | 39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 16 | Exercise / conversion · M | +12,394 | $9.88 | +$122K | 52,294 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 10 | Open-market sale · S | −10,185 | $17.62 | −$179K | 39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 10 | Exercise / conversion · M | +10,185 | $8.04 | +$81.9K | 50,085 |
| Doyle Mittie | Chief Medical Officer | Aug 28 | Disclosed 10b5-1 sale · S | −679 | $20.00 | −$13.6K | 51,776 |
| Doyle Mittie | Chief Medical Officer | Aug 28 | Exercise / conversion · M | +679 | $8.04 | +$5.46K | 52,455 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 18 | Open-market sale · S | −31,031 | $20.05 | −$622K | 39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 18 | Exercise / conversion · M | +31,031 | $9.88 | +$307K | 70,931 |
| Doyle Mittie | Chief Medical Officer | Aug 17 | Disclosed 10b5-1 sale · S | −1,000 | $20.00 | −$20K | 51,776 |
| Doyle Mittie | Chief Medical Officer | Aug 17 | Exercise / conversion · M | +1,000 | $12.65 | +$12.7K | 52,776 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17 | Open-market sale · S | −3,749 | $19.94 | −$74.8K | 39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17 | Open-market sale · S | −37,945 | $19.85 | −$753K | 43,649 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17 | Exercise / conversion · M | +2,876 | $9.88 | +$28.4K | 81,594 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17 | Exercise / conversion · M | +37,945 | $9.88 | +$375K | 78,718 |
| Riley Jennifer | Chief Strategy Officer | Aug 11 | Open-market sale · S | −2,655 | $19.59 | −$52K | 37,041 |
| Doyle Mittie | Chief Medical Officer | Aug 10 | Disclosed 10b5-1 sale · S | −679 | $20.00 | −$13.6K | 51,776 |
| Doyle Mittie | Chief Medical Officer | Aug 10 | Exercise / conversion · M | +679 | $8.04 | +$5.46K | 52,455 |
| Doyle Mittie | Chief Medical Officer | Jul 27 | Disclosed 10b5-1 sale · S | −1,000 | $20.00 | −$20K | 51,776 |
| Doyle Mittie | Chief Medical Officer | Jul 27 | Exercise / conversion · M | +1,000 | $12.65 | +$12.7K | 52,776 |
| Doyle Mittie | Chief Medical Officer | Jun 30 | Disclosed 10b5-1 sale · S | −4,654 | $20.00 | −$93.1K | 51,776 |
Loading...
